Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 6/25/2025

Thyroid Nodule Management

Clinical Follow-up and Surveillance

  • Clinical follow-up with ultrasound surveillance is recommended for thyroid nodules classified as Bethesda II, with the first follow-up ultrasound at 12-18 months and subsequent ultrasounds at 3-5 year intervals if stable 1
  • The American Thyroid Association (ATA) guidelines do not recommend routine FNA for nodules ≤10 mm unless high-risk features are present, and active surveillance is appropriate for these small nodules 2, 3
  • For nodules ≥1 cm, regular ultrasound follow-up is recommended, with monitoring parameters including size, echogenicity, margins, vascularity, and calcifications 1

Nodule Size Considerations

  • Less intensive surveillance may be appropriate for nodules <1 cm, while regular ultrasound follow-up is recommended for nodules ≥1 cm 1
  • Nodule growth of ≥3 mm in greatest dimension is an indication for repeat FNA 2

Risk Stratification

  • Ultrasound features can help further stratify risk in Bethesda II nodules, with low-risk features including purely cystic, spongiform, or predominantly cystic nodules, and high-risk features including irregular margins, microcalcifications, and taller-than-wide shape 2
  • Each nodule should be evaluated individually based on its sonographic features, and the most suspicious nodule should guide management decisions 2

Management Approach

  • No immediate surgical intervention is required for Bethesda II nodules unless there are specific high-risk features present, such as compressive symptoms, cosmetic concerns, or patient preference after thorough discussion of risks/benefits 1
  • The management of Bethesda II thyroid nodules should follow a risk-stratified approach, with ongoing vigilance necessary due to the potential for false-negative results 2, 3

REFERENCES